DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1093911
Title:
Dual Benefit of TGFB Inhibition on Tumor Control in the Context of Radiotherapy for Breast Cancer Brain Metastases
Report Date:
2019-02-01
Abstract:
This project evaluates whether transforming growth factor beta (TGF) inhibition during radiation therapy (RT) to breast cancer brain metastases (BCBM) provides greater therapeutic benefit than RT alone using a robust proof-of-concept therapeutic protocol in combination with innovative functional imaging. Successful demonstration that TGF inhibition increases durable RT response that may augment immunotherapy in preclinical BCBM models would provide a strong rationale for trials of clinically viable drugs that block TGF-beta signaling with gamma-knife stereotactic radiosurgery (GKSRS) for women with metastatic disease. We incorporate molecular imaging of active TGF to assess target levels, drug delivery, therapeutic response via tumor metabolism, and identify potential immune mediated responses that will enable rapid clinical translation of combined RT and TGF inhibitory drug regimens.
Document Type:
Conference:
Journal:
Pages:
14
File Size:
1.50MB
W81XWH-17-1-0032
(W81XWH1710032);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
